Therapeutic potential of ERK5 targeting in triple negative breast cancer


Triple negative breast cancers (TNBCs) account for 15% of all breast cancers, and represent one of the most aggressive forms of the disease, exhibiting short relapse-free survival. In contrast to other breast cancer subtypes, the absence of knowledge about the etiopathogenic alterations that cause TNBCs force the use of chemotherapeutics to treat these… (More)


5 Figures and Tables

Slides referencing similar topics